76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Recursion Pharmaceuticals Inc
Open
SectorHealthcare
4.54 7.58
Overview
Share price change
24h
Min
4.17
Max
4.54
Income | -24M -202M |
|---|---|
Sales | 10M 15M |
EPS | -0.5 |
Profit margin | -1,373.259 |
Employees | 800 |
EBITDA | -26M -191M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +56.61% upside |
Next Earnings | 7 Aug 2025 |
|---|
Market Cap | -431M 1.9B |
|---|---|
Previous open | -3.04 |
Previous close | 4.54 |
News Sentiment
By Acuity
100%
0%
371 / 382 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Recursion Pharmaceuticals Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Recursion Pharmaceuticals Inc Forecast
Price Target
By TipRanks
56.61% upside
12 Months Forecast
Average 6.75 USD 56.61%
High 8 USD
Low 3 USD
Based on 5 Wall Street analysts offering 12 month price targets forRecursion Pharmaceuticals Inc - Dist in the last 3 months.
Sentiment
By Acuity
371 / 382 Healthcare
News Sentiment
Very Strong Bearish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
